Evidence map›Paper›PMID 26301077›Full record

ArticleTherapeutic advances in psychopharmacology2015

Antipsychotic therapeutic drug monitoring: psychiatrists' attitudes and factors predicting likely future use.

Suzanne Law, Peter M Haddad, Imran B Chaudhry, Nusrat Husain, Richard J Drake, Robert J Flanagan, Anthony S David, Maxine X Patel

Abstract read
In one paragraph

Article in Therapeutic advances in psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suzanne LawInstitute of Psychiatry, Psychology and Neuroscience, London, UK.
Peter M HaddadGreater Manchester West NHS Foundation Trust, Manchester, UK.
Imran B ChaudhryUniversity of Manchester, Manchester, UK.
Nusrat HusainUniversity of Manchester, Manchester, UK.
Richard J DrakeManchester Mental Health and Social Care Trust, Manchester, UK.
Robert J FlanaganInstitute of Psychiatry, Psychology and Neuroscience, London, UK.
Anthony S DavidInstitute of Psychiatry, Psychology and Neuroscience, London, UK.
Maxine X PatelInstitute of Psychiatry, King's College London, Box 68, 16 DeCrespigny Park, London SE5 8AF, UK.

Funding

Department of Health NIHR/CS/009/010
6 · The paper itself

Abstract

backgroundThis study aimed to explore predictive factors for future use of therapeutic drug monitoring (TDM) and to further examine psychiatrists' current prescribing practices and perspectives regarding antipsychotic TDM using plasma concentrations.

methodA cross-sectional study for consultant psychiatrists using a postal questionnaire was conducted in north-west England. Data were combined with those of a previous London-based study and principal axis factor analysis was conducted to identify predictors of future use of TDM.

resultsMost of the 181 participants (82.9%, 95% confidence interval 76.7-87.7%) agreed that 'if TDM for antipsychotics were readily available, I would use it'. Factor analysis identified five factors from the original 35 items regarding TDM. Four of the factors significantly predicted likely future use of antipsychotic TDM and together explained 40% of the variance in a multivariate linear regression model. Likely future use increased with positive attitudes and expectations, and decreased with potential barriers, negative attitudes and negative expectations. Scientific perspectives of TDM and psychiatrist characteristics were not significant predictors.

conclusionMost senior psychiatrists indicated that they would use antipsychotic TDM if available. However, psychiatrists' attitudes and expectations and the potential barriers need to be addressed, in addition to the scientific evidence, before widespread use of antipsychotic TDM is likely in clinical practice.

Indexed as

antipsychoticsattitudedoseplasma concentrationschizophreniatherapeutic drug monitoring

Identifiers

PMID26301077
PMCPMC4535047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.